N/A N=53 Timing Estrogen After MenoPaUSe
Insulin Resistance
Primary: Insulin-mediated Glucose Disposal Rate (Hyperinsulinemic-euglycemic Clamp) — 11.7; 11.5; 12.2; 10.7 mg/kg FFM/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 Postmenopausal Women Estrogen and Progesterone Infusion
Postmenopause · Aging
Primary: Effect of Aging on Estrogen Negative Feedback on LH — -52.8; -53.2 % change from baseline — p=0.90
N/A N=30 Early Menopause Hormone Treatment and Cognition
Menopausal Syndrome
Primary: Changes in Brain Activation Patterns in Verbal Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans — .14; .13; .05; .13 percent BOLD signal…
N/A N=38 Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression
Menopausal and Other Perimenopausal Disorders
Primary: Hot Flashes — 10.3; 7.944 scores on a scale
Phase 4 N=34 Estrogen Variability and Irritability During the Menopause Transition
Menopause · Irritable Mood
Primary: Mean IDAS Ill Temper Scale Score Over Time — 6.19; 6.02 score on a scale — p=0.09
Phase 3 N=172 Perimenopausal Estrogen Replacement Therapy Study
Perimenopause · Menopause · Depression
Primary: Change in Depressive Symptoms as Indicated by The Center for Epidemiologic Studies Depression Scale (CES-D) — 1.04; -1.02 units on a scale
Phase 2 N=190 Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms
Vasomotor Symptoms (VMS)
Primary: Percentage of Subjects With Adverse Events — 56.7 percentage of subjects
Phase 2 N=374 MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
Menopause Hot Flashes
Primary: Change From Baseline in the Average Daily Frequency of Moderate to Severe VMS at Weeks 4 and 12 — -1.92; -2.75; -2.75; -1.39 VMS per day
Phase 2 N=96 Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women
Human Immunodeficiency Virus
Primary: Safety of Dapivirine (25 mg) Administered in a Silicone Elastomer Vaginal Matrix Ring in HIV-uninfected Postmenopausal Women, When Inserted Once Every 4 Weeks During 12…
N/A N=92 Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women
Arterial Stiffening · Aging · Menopause
Primary: Arterial Stiffness (Carotid Artery Compliance) During Saline — 1.31; 1.34; 0.90; 1.02 mm2/mm Hg×10-1
Phase 2 N=102 Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause
Hot Flashes
Primary: Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 8 — 82.44; 83.18; 37.3; 28.5 Hot flashes — p=0.0177
Phase 3 N=1,271 Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
Hypoactive Sexual Desire Disorder
Primary: Incidence of Endometrial Hyperplasia in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Not Using Concomitant Estrogen and Progestin, Year 1…
N/A N=1,036,294 A Study to Learn More About the Menopausal Hormone Therapies in Korea
Menopause · Bone Demineralization
Primary: Number of Women Who Visited Hospitals for Menopausal Symptoms Distributed Per Year — 786616; 787425; 791890; 818749 Participants
N/A N=410 MyMenoPlan: Online Resource for Improving Women's Menopause Knowledge and Informed Decision-making
Menopause · Premenopause · Postmenopause
Primary: Perceived Quality of Information — 4.1; 3.7 score on a scale — p=<.001
Phase 4 N=63 Raloxifene and Rimostil for Perimenopause-Related Depression
Perimenopausal Depression · Depression
Primary: Center for Epidemiologic Studies-Depression Scale (CES-D) — 27.4; 29.1; 28.8; 24.6 Units on a scale
Phase 4 N=79 Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women
Overweight
Primary: Body Composition: Dual-energy X-ray Absorptiometry Method — 44.5; 48.8; 43.8; 46.6 percent of total fat mass
Phase 3 N=189 Progesterone for Perimenopausal Night Sweats
Hot Flushes · Night Sweats
Primary: Vasomotor Symptoms (VMS)/ VMS Score - at 12 Weeks — 5.5; 7.1 Units of Vasomotor Symptom Score
Phase 1 N=29 A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women
Postmenopausal Symptoms
Primary: Immunohistochemistry (IHC) Proliferative Effects Measurement — 0.73; 0.43; 0.25 Square root of % positive stained cells — p=<0.001
Phase 4 N=24 Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function
Cardiovascular Diseases
Primary: Brachial Artery Reactivity % Flow Mediated Dilation (BAR %FMD) — 5.49; 3.39 % FMD after 6 weeks of treatment — p=0.04
Phase 3 N=20 Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women
Menopause
Primary: Vaginal Cytokines at Baseline — 2.73; 3.19; 0.12; 0.04 pg/ug protein
N/A N=6 Effects of Estrogen Deficiency on Energy Expenditure
Obesity
Primary: Brown Adipose Tissue Activity — 3.9; 4.0 Standard uptake value (SUV) — p=0.84
Phase 3 N=570 24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
Hot Flashes
Primary: Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 12. — 10.83; 10.90; -4.13; -2.71 Hot flashes per day — p=<0.0001
Phase 3 N=1,831 A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
Hot Flashes
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 391; 415; 389; 106 participants
N/A N=19 Role of T-cells in Post-Menopausal Osteoporosis
Osteoporosis
Primary: Changes in T-cell Activation Measured by Flow Cytometry, Specifically the Percentage of CD3+CD69+ T-cells — 3.6; 1.8 percentage of CD3 positive cells
N/A N=37 Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study
Myocardial Ischemia
Primary: Inducible Myocardial Ischemia — -13.8; -7.0 percent changed in PCR/ATP ratio — p=0.36
Phase 3 N=1,845 A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
Menopause
Primary: Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS) — -40.6; -35.1; -33.6; -38.9 weekly hot flushes — p=<0.001
Phase 2 N=133 Homeopathic Treatment for Depression in Peri- and Postmenopausal Women
Moderate Depression · Menopausal and Postmenopausal Disorders
Primary: Change From Baseline in 17-item Hamilton Rating Scale for Depression at 6 Weeks. — 9.9; 11.7; 15 Units in Hamilton Scale — p=<0.05
Phase 3 N=530 DHEA Against Vaginal Atrophy - Safety Study of 12 Months
Vaginal Atrophy
Primary: Long-term Safety of Intravaginal Prasterone (DHEA): Endometrium — 421; 36 Participants
Phase 1 N=30 Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women
Healthy
Primary: Mean Baseline GH Concentration — 0.23; 0.096 ug/L — p=<0.05
Early Phase 1 N=8 Raising Insulin Sensitivity in Post Menopause
Menopause
Primary: Effect of CE/BZA (TSEC) on Body Composition — 91.3; 90.6; 45.5; 45.7 Kilograms